T. Chen Fong
Angel Investor
Calgary, Canada
T. Chen Fong is a seed investor in Calgary focused on Software and Artificial Intelligence. Dr. Fong is a Professor Emeritus at the Faculty of Medicine, University of Calgary. He was formerly the Head of the Department of Radiology at the University of Calgary and the Calgary Health Region. Dr. Fong is active in funding and nurturing start-up companies. Over the past two decades, he funded over 50 companies in diverse technology sectors,with an emphasis in medical devices. Dr. Fong is the co-founder and board member of Calgary Scientific Inc. and is also on the board of Clarius Mobile Health, Cohesic Inc. and Innovere Medical. In addition to seed investing, Dr. Fong is active in the Calgary community sitting on six charitable boards and foundations.In 2015, Dr. Fong joined the Creative Destruction Lab (CDL) at the University of Toronto business school as a mentor. CDL helps young entrepreneurs to shape or pivot their nascent ideas. He is widely credited with launching CDL at the Haskayne School of Business at the University of Calgary, bringing together seasoned business leaders from Alberta, Canada and the US to grow budding companies. Dr. Fong is on the Strategic Advisory Board of CDL and a Fellow of CDL in Toronto, Montreal, Calgary and Vancouver. In 2017, Dr. Fong was named to the Order of Canada for his contribution to medical technology innovation and philanthropy.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries T. Chen Fong invests in
Stages T. Chen Fong invests in
Countries T. Chen Fong invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $227k–$10M
Investment Focus
Industry
- Software 6 (50%)
- Artificial Intelligence 4 (33%)
- Biotechnology 3 (25%)
- Energy 2 (17%)
- CleanTech 2 (17%)
Stage
- Seed 9 (75%)
- Angel 1 (8%)
- Pre-Seed 1 (8%)
- Funding Round 1 (8%)
Country
- Canada 9 (75%)
- Singapore 1 (8%)
- United States 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| EZee Assist provides instant answers to franchisee operational questions. Continue using preferred channels of support and start receiving instant answers and support. | $1.4M / Pre-Seed / Dec 07, 2023 | ||
| SunGreenH2 uses nanotechnology and advanced materials to create the world's highest performance electrolysers for green hydrogen production at a low cost. The company has developed a modular, scalable electrolyser stack using its proprietary high performance electrolyser hardware components which it designs, develops and manufactures in-house.By opening the door to widespread adoption of green hydrogen in industry, mobility and energy storage, SunGreenH2 is unlocking sustainable, scalable, low cost on-site green hydrogen production globally. Our proprietary platform technology is the result of 10+ years research in electrochemistry and nanotechnology.SunGreenH2 was founded in 2020 and is headquartered in Singapore with offices in Melbourne and London. | $3M / Seed / Aug 18, 2022 | ||
| Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers. | $5M / Seed / Jul 21, 2022 | ||
| Cadence is an integrated, end-to-end solution that streamlines both the estate planning and settlement processes. Businesses that use Cadence can support their clientele without adding extra work to their plate, and individuals that use Cadence are given more time to focus on living, grieving, and healing. | $931.4K / Seed / Jun 29, 2022 | ||
| Signal 1’s AI platform helps hospitals tackle these by integrating AI-driven insights directly into existing workflows, delivering improved patient outcomes, enhanced hospital efficiency and reduced stress for front-line workers. | $10M / Seed / Apr 25, 2022 | ||
| Monark is a digital leadership guide that enables growth through one simple app. Monark provides a full-cycle, tailored, and integrated experience to leaders of all levels. Their patented platform and micro-content are accessible anywhere, at any time, and on any device. | $600K / Angel / Mar 21, 2021 | ||
| Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics. The company develops a comprehensive approach to oncology diagnostics and uses deep learning to derive actionable insights into oncology treatment.It was founded in 2020 by Akshay Nanduri and Salmaan Ahmed and is based in San Carlos, California,United States. | $6M / Seed / Dec 02, 2020 | ||
| EcoPackers use the power of plants to create 100% biodegradable alternatives to traditional plastic inputs. Our eco-resins allow plastic manufacturers worldwide to create innovative non-toxic and compostable single use packaging items. | $4.3M / Seed / Dec 09, 2019 | ||
| Beatdapp offers a tracking system that authenticates, verifies, and validates media streamed in real-time.The service reduces the tracking discrepancies between Digital Service Providers (DSPs) and rights holders, increasing royalty revenue for rights holders while limiting legal exposure to royalty lawsuits for DSPs. Think of it like a PWC formusic play count. | $2.4M / Seed / Oct 14, 2019 | ||
| Currently, inline inspection in the oil and gas sector is a series of staged engineering events, designed to assess the condition of pipeline assets. It is costly, infrequent, and only addresses those lines that are within reach. In fact, it is estimated that 40% of the world’s pipelines are unpiggable. The vulnerabilities between inspections,which are typically years apart, or the inability to conduct inspections at all, puts the world’s aging pipeline infrastructure at risk. In order to address these issues, we have focused on changing the economics, the technology, and the workflow associated with inline inspection. We have introduced the industry’s first self-serve inspection model that eliminates significant engineering and downtime costs. We have developed miniature, multi sensor Pipers® technology that freely flows within any and all active pipelines, regardless of location, condition, material or configuration. This technology is capable of inspecting pipelines as small as 2 inches in diameter, and surveying for leaks, geometric defects, magnetic anomalies, and deposits in a single run. Further, we have reduced the cost of inline inspection by a factor of 10, making it possible for integrity programs to be more present, more often, across all of their assets. Finally, such accessible technology has given us the opportunity to work with a complete range of clients – large and small, private and public – resulting in rich datasets libraries that offer unprecedented contextual analysis and continuous advancement of our data analytics capabilities. Our approach provides clients with uninterrupted access to up-to-date condition-critical data, allowing them to optimize planning, decision-making, and actions. | $227K / Seed / Oct 01, 2017 | ||
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does T. Chen Fong invest in?
T. Chen Fong invests primarily in Software, Artificial Intelligence and Biotechnology startups, most often at Seed and Angel stage. Most of the 12 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is T. Chen Fong's check size?
T. Chen Fong typically joins rounds of $227k–$10M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds T. Chen Fong participates in.
How do I contact T. Chen Fong?
Public channels for T. Chen Fong include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did T. Chen Fong last invest?
The most recent investment recorded for T. Chen Fong closed in Dec 2023. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
